- CA$32.65m
- CA$33.45m
- 42
- 64
- 26
- 40
Annual income statement for VVT Med, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.295 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | -0.141 | 0 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | -5.9 | 0.253 | 0.138 | 0.184 | 0.158 |
| Operating Profit | 6.2 | -0.253 | -0.138 | -0.184 | -0.158 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 6.2 | -0.243 | -0.138 | -0.184 | -0.158 |
| Net Income After Taxes | 6.2 | -0.243 | -0.138 | -0.184 | -0.158 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 6.2 | -0.243 | -0.138 | -0.184 | -0.158 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 6.2 | -0.243 | -0.138 | -0.184 | -0.158 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.17 | -0.096 | -0.054 | -0.072 | -0.062 |